Thyroid cancer

DW Chen, BHH Lang, DSA McLeod, K Newbold… - The Lancet, 2023 - thelancet.com
The past 5–10 years have brought in a new era in the care of patients with thyroid cancer,
with the introduction of transformative diagnostic and management options. Several …

Anaplastic thyroid carcinoma: an update

A Jannin, A Escande, A Al Ghuzlan, P Blanchard… - Cancers, 2022 - mdpi.com
Simple Summary Anaplastic thyroid carcinoma (ATC) has a dismal prognostic.
Chemotherapy and radiotherapy are the mainstem options for patients with ATC. In selected …

[HTML][HTML] Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

V Subbiah, RJ Kreitman, ZA Wainberg, JY Cho… - Annals of …, 2022 - Elsevier
Background Combined therapy with dabrafenib plus trametinib was approved in several
countries for treatment of BRAF V600E-mutant anaplastic thyroid cancer (ATC) based on an …

[HTML][HTML] Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era

J Capdevila, A Awada, D Führer-Sakel… - Cancer Treatment …, 2022 - Elsevier
Most malignant thyroid tumours are initially treated with surgery or a combination of surgery
and radioactive iodine (RAI) therapy. However, in patients with metastatic disease, many …

Anaplastic thyroid cancer: new horizons and challenges

A Maniakas, M Zafereo… - … and Metabolism Clinics, 2022 - endo.theclinics.com
Anaplastic Thyroid Cancer - Endocrinology and Metabolism Clinics Skip to Main Content
Advertisement Endocrinology and Metabolism Clinics Log in Register Log in Subscribe Claim …

[HTML][HTML] Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities

L Zhang, Q Feng, J Wang, Z Tan, Q Li, M Ge - Biochimica et Biophysica …, 2023 - Elsevier
Thyroid cancer (TC) is the most prevalent endocrine malignant tumor. Surgery,
chemotherapy, radiotherapy, and radioactive iodine (RAI) therapy are the standard TC …

Anaplastic thyroid cancer: An update

SN Rao, RC Smallridge - Best Practice & Research Clinical Endocrinology …, 2023 - Elsevier
Anaplastic thyroid cancer (ATC) is one of the most lethal of all cancers. It is more common in
women and occurs primarily in older patients. ATC has a median overall survival of 3–5 …

Combination targeted therapy with pembrolizumab and lenvatinib in progressive, radioiodine-refractory differentiated thyroid cancers

JD French, BR Haugen, FP Worden… - Clinical Cancer …, 2024 - aacrjournals.org
Purpose: Lenvatinib, a potent multikinase inhibitor, improves progression-free survival (PFS)
in patients with radioiodine (RAI)-refractory differentiated thyroid cancer; however, most …

Peptide receptor radionuclide therapy in thyroid cancer

S Gubbi, CA Koch, J Klubo-Gwiezdzinska - Frontiers in endocrinology, 2022 - frontiersin.org
The treatment options that are currently available for management of metastatic, progressive
radioactive iodine (RAI)-refractory differentiated thyroid cancers (DTCs), and medullary …

Translating the immune microenvironment of thyroid cancer into clinical practice

LL Cunha, LS Ward - Endocrine-Related Cancer, 2022 - erc.bioscientifica.com
Thyroid cancer is an excellent model for studying tumor immune microenvironment, as it
often shows local signs of an immune response. The tumor immune microenvironment of …